A murine interleukin-4-Ig fusion protein regulates the expression of Th1- and Th2-specific cytokines in the pancreas of NOD mice

Hormone and Metabolic Research

Volumn 34, Issue 10, 2002, Pages 561-569

  Walz, Markus ^a   Overbergh, L ^b   Mathieu, C ^b   Kolb, H ^a   Martin, S ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Cyclophosphamide; Fusion Proteins; IL 4 Ig; NOD Mice; Th1 Th2 Cytokines

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKINE; FC RECEPTOR; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN G2A; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; RNA; TUMOR NECROSIS FACTOR ALPHA; IMMUNOGLOBULIN G; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE EXPRESSION REGULATION; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; MOUSE; NONHUMAN; PANCREAS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; TH1 CELL; TH2 CELL; ANIMAL; BACULOVIRUS; BIOSYNTHESIS; DOWN REGULATION; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; METABOLISM; NONOBESE DIABETIC MOUSE;

ANIMALIA; MURINAE;

ANIMALS; BACULOVIRIDAE; DIABETES MELLITUS, TYPE 1; DOWN-REGULATION; FEMALE; IMMUNOGLOBULIN G; INTERFERON TYPE II; INTERLEUKIN-4; MICE; MICE, INBRED NOD; PANCREAS; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TH1 CELLS; TH2 CELLS; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1842864843     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-35417     Document Type: Article

References (59)

1. Rothe H, Hausmann A, Kolb H. Immunoregulation during disease progression in prediabetic NOD mice: inverse expression of arginase and prostaglandin H synthase 2 vs. interleukin-15. Horm Metab Res 2002; 34: 7-12
2. Campbell IL, Kay TW, Oxbrow L, Harrison LC. Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J Clin Invest 1991; 87: 739-742
3. Rothe H, Faust A, Schade U, Kleemann R, Bosse G, Hibino T, Martin S, Kolb H. Cyclophosphamide treatment of female non-obese diabetic mice causes enhanced expression of inducible nitric oxide synthase and interferon-gamma, but not of interleukin-4. Diabetologia 1994; 37: 1154-1158
4. von Herrath MG, Oldstone MBA. lnterferon-γ is essential for destruction of beta-cells and development of insulin-dependent diabetes mellitus. J Exp Med 1997; 185: 531-539
5. Wang B, André I, Gonzalez A, Katz JD, Aguet M, Benoist C, Mathis D. Interferon-γ impacts at multiple points during the progression of autoimmune diabetes. Proc Natl Acad Sci USA 1997; 94: 13 844-13849
6. Fujihira K, Nagata M, Moriyama H, Yasuda H, Arisawa K, Nakayama M, Maeda S, Kasuga M, Okumura K, Yagita H, Yokono K. Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice. Diabetes 2000; 49: 1998-2006
7. Debray-Sachs M, Carnaud C, Boitard C, Cohen H, Gresser I, Bedossa P, Bach JF. Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma. J Autoimmun 1991; 4: 237-248
8. Nicoletti F, Zaccone P, Di Marco R, Mauro MD, Margo G, Grasso S, Muggini L, Meroni PL, Garotta G. The effects of a nonimmunogenic form of murine soluble interferon-γ receptor on the development of autoimmune diabetes in the NOD mouse. Endocrinol 1996; 137: 5567-5575
9. Hunger RE, Carnoud C, Garcia I, Vassalli P, Mueller C. Prevention of autoimmune diabetes mellitus in NOD mice by transgenic expression of soluble tumor necrosis factor receptor p55. Eur J Immunol 1997; 27: 255-261
10. Nicoletti F, Di Marco R, Barcelline W, Margo G, Schorlemmer HU, Kurrle R, Lunetta M, Grasso S, Zaccone P, Meroni PL. Protection from experimental autoimmune diabetes in NOD mouse with soluble IL-1 receptor. Eur J Immunol 1994; 24: 1843-1847
11. Rapoport MJ, Jaramillo A, Zipris D, Lazarus AH, Serreze DV, Leiter EH, Cyopick P, Danska JS, Delovitch TL. Interleukin 4 reverses T-cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993; 178: 87-99
12. Pennline KJ, Roque-Gaffney E, Monahan M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 1994; 71: 169-175
13. Zaccone P, Phillips J, Conget I, Gomis R, Hskins K, Adrian M, Bendtzen K, Cooke A, Nicoletti F. Interleukin-13 prevents autoimmune diabetes in NOD mice. Diabetes 1999; 48: 1522-1528
14. Rothe H, Hausmann A, Casteels K, Okamura H, Kurimoto M, Burkart V, Mathieu C, Kolb H. IL-18 inhibits diabetes development in nonobese diabetic mice by counterregulation of Th1-dependent destructive insulitis. J Immunol 1999: 164: 1230-1236
15. Swain SL, Weinberg AD, English M, Huston G. IL-4 directs the development of Th2-like helper effectors. J Immunol 1990; 145: 3796-3806
16. Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmann H, Köhler G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993; 362: 245-248
17. Fox CJ, Danska JS. IL-4 expression at the onset of islet inflammation predicts nondestructive insulitis in nonobese diabetic mice. J Immunol 1997; 158: 2414-2424
18. Ablamunits V, Quintana F, Reshef T, Elias D, Cohen IR. Acceleration of autoimmune diabetes by cyclophosphamide is associated with an enhanced IFN-gamma secretion pathway. J Autoimmun 1999; 13: 383-392
19. Sarvetnick N, Liggitt D, Pitts SL, Hansen SE, Stewart TA. Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class II MHC and interferon-gamma. Cell 1988; 52: 773-782
20. Hultgren B, Huang X, Dybdal N, Stewart TA. Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice. Diabetes 1996; 45: 812-817
21. Martin S, Heidenthal E, Schulte B, Rothe H, Kolb H. Soluble forms of intercellular adhesion molecule-1 inhibit insulitis and onset of autoimmune diabetes. Diabetologia 1998; 41: 1298-1303
22. Favre N, Erb P. Use of the CTL44 cell line, a derivative of CTL/L cells, to identify and quantify mouse interleukin-4 by bioassay. J Immunol Meth 1993; 164: 213-220
23. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159
24. Overbergh L, Valckx D, Waer M, Mathieu C. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine 1999; 11: 305-312
25. Faust A, Rothe H, Schade U, Lampeter E, Kolb H. Primary nonfunction of islet grafts in autoimmune diabetic nonobese diabetic mice is prevented by treatment with interleukin-4 and interleukin-10. Transplantation 1996; 62: 648-652
26. Cameron MJ, Arreaza GA, Zucker P, Chensue SW, Strieter RM, Chakrabarti S, Delovitch TL. IL-4 prevents insulitis and insulin dependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function. J Immunol 1997; 159: 4686-4692
27. Tominaga Y, Nagata M, Yasuda H, Okamoto N, Arisawa K, Moriyama H, Miki M, Yokono K, Kasuga M. Administration of IL-4 prevents autoimmune diabetes but enhances pancreatic insulitis in NOD mice. Clin Immunol Immunopath 1998; 86: 209-218
28. Mueller R. Krahl T, Sarvetnick N, Pancreatic expression of interleukin4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 1996; 184: 1093-1099
29. Gallichan WS, Balasa B, Davies JD, Sarvetnick N. Pancreatic IL-4 expression results in islet-reactive Th2 cells that inhibit diabetogenic lymphocytes in the nonobese diabetic mouse. J Immunol 1999; 163: 1696-1703
30. Chang Y, Prud'homme GJ. Intramuscular administration of expression plasmids encoding interferon-γ receptor/IgG1 or IL-4/IgG1 chimeric proteins protects from autoimmunity. J Gene Med 1999; 1: 415-423
31. Thomas HE, Parker JL, Schreiber RD, Kay TWH. IFN-γ action on pancreatic beta cells causes class I MHC upregulation but not diabetes. J Clin Invest 1998; 102: 1249-1257
32. Serreze DV, Post CM, Chapman HD, Johnson EJ, Lu B, Rothman PB. Interferon-γ receptor signaling is dispensable in the development of autoimmune type 1 diabetes in NOD mice. Diabetes 2000; 49: 2007-2011
33. Xiang M, Zaccone P, Di Marco R, Harris R, Magro G, Di Mauro M, Meroni PL, Garotta G, Nicoletti F. Failure of exogenously administered interferon-gamma or blockage of endogenous interleukin-4 with specific inhibitors to augment the incidence of autoimmune diabetes in male NOD mice. Autoimmunity 1999; 30: 71-80
34. Suk K, Kim S, Kim Y-H, Kim K-A, Chang I, Yagita H, Shong M, Lee M-S. IFN-γ/TNF-α synergism as the final effector in autoimmune diabetes: A key role for STAT1/IFN regulatory factor-1 pathway in pancreatic β cell death. J Immunol 2001; 166: 4481-4489
35. Levings MK, Schrader JW. IL-4 inhibits the production of TNF-α and IL-12 by STAT6-dependent and -independent mechanisms. J Immunol 1999; 162: 5224-5229
36. Essner R, Rhoades K, McBride WH, Morton DL. Economou JS. IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. J Immunol 1989; 142: 3857-3861
37. Grewal IS, Grewal KD, Wong FS, Picarella DE, Janeway CA Jr, Flavell RA. Local expression of transgene encoded TNF alpha in islets prevents autoimmune diabetes in nonobese (NOD) mice by preventing the development of auto-reactive islet-specific T-cells. J Exp Med 1996; 184: 1963-1974
38. Jacob CO, Aiso S, Michie SA, McDevitt HO, Acha-Orbea H. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin 1. Proc Natl Acad Sci USA 1990; 87: 968-972
39. Picarella DE, Kratz A, Li CB, Ruddle NH, Flavell RA. Transgenic tumor necrosis factor (TNF)-alpha production in pancreatic islets leads to insulitis, not diabetes. Distinct patterns of inflammation in TNF-alpha and TNF-beta transgenic mice. J Immunol 1993; 150: 4136-4150
40. Green EA, Flavell RA. Tumor necrosis factor-alpha and the progression of diabetes in non-obese diabetic mice. Immunol Rev 1993; 169: 1122
41. Loots GG, Locksley RM, Blankespoor CM, Wang ZE. Miller W, Rubin EM, Frazer KA. Identification of a coordinate regulator of interleukins 4, 13, and 5 by cross-species sequence comparison. Science 2000; 288: 136-140
42. Trembleau S, Penna G, Bosi E, Mortara A, Gately MK, Adorini L. Interleukin-12 administration induces T helper type 1 cells and accelerates autoimmune disease in NOD mice. J Exp Med 1995; 181: 817-821
43. 2. Diabetologia 1997; 40: 641-646
44. Takenaka H, Maruo S, Yamamoto N, Wysocka M, Ono S, Kobayashi M, Yagita H, Okumura K, Hamaoka T, Trinchieri G, Fujiwara H. Regulation oft cell-dependent and -independent IL-12 production by the three Th2-type cytokines IL-10, IL-6, and IL-4. J Leukoc Biol 1997; 61: 80-87
45. Wogensen L, Lee M-S, Sarvetnick N. Production of interleukin 10 by islet cells accelerates immune-mediated destruction of β cells in nonobese diabetic mice. J Exp Med 1994; 179: 1379-1384
46. Balasa B, La Cava A, Van Gunst K, Mocnik L, Balakrishna D, Nguyen N, Tucker L. Sarvetnick N. A mechanism for IL-10-mediated diabetes in the nonobese diabetic (NOD) mouse: ICAM-1 deficiency blocks accelerated diabetes. J Immunol 2000; 165: 7330-7337
47. Lee MS, Mueller R, Wicker LS, Peterson LB, Sarvetnick N. IL-10 is necessary and sufficient for autoimmune diabetes in conjunction with NOD MHC homozygosity. J Exp Med 1996; 183: 2663-2668
48. Zheng XX, Steele AW, Hancock WW, Stevens AC, Nickerson PW, Prabir R-C, Yan T, Tian Y, Strom TB. A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice. J Immunol 1997; 158: 4507-4513
49. Falcone M, Yeung B, Tucker L, Rodriguez E, Krahl T, Sarvetnick N. IL-4 triggers autoimmune diabetes by increasing self-antigen presentation within the pancreatic islets. Clin Immunol 2001; 98: 190-199
50. Allison J, Malcom L, Chosich N, Miller JFAP. Inflammation but not autoimmunity occurs in transgenic mice expressing constitutive levels of IL-2 in islet β cells. Eur J Immunol 1992; 22: 1115-1121
51. Cameron MJ, Arreaza GA, Grattan M, Meagher C, Sharif S, Burdick MD, Strieter RM, Cook DN, Delovitch TL. Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type I diabetes. J Immunol 2000; 165: 1102-1110
52. Fahey TJ, Tracey KJ, Tekamp-Olson P, Cousens LS, Jones WG, Shires GT, Cerami A, Sherry B. Macrophage inflammatory protein 1 modulates macrophage function. J Immunol 1992; 148: 2764-2769
53. Stassi G, Maria RD, Trucco G, Rudert W, Testi R, Galluzo A, Giordano C, Trucco M. Nitric oxide primes pancreatic β cells for Fas-mediated destruction in insulin-dependent diabetes mellitus. J Exp Med 1997; 186: 1193-1200
54. Zheng XX, Steele AW, Hancock WW, Kawamoto K, Li XC, Nickerson PW. Li Y, Tian Y. Strom TB. IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice. J Immunol 1999; 163: 4041-4048
55. Feng X, Zheng XX, Yi S, Lehnert AM, Strom TB, O'Connell PJ. IL-10/Fc inhibits macrophage function and prolongs pancreatic islet xenograft survival. Transplantation 1999; 68: 1775-1783
56. Kurschner C, Ozmen L, Garotta G, Gembic Z. IFN-γ-receptor-Ig fusion proteins. Half-life, immunogenecity and in vivo activity. J Immunol 1992; 144: 4096-4100
57. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmet MB, Blosch CM. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-147
58. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A, Lowe NJ, Krueger G, Brown MJ, Weiner RS, Birkhofer MJ, Warner GL, Berry KK, Linsley PS, Krueger JG, Ochs HD, Kelley SL, Kang S. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103: 1243-1252
59. Berman MA, Sandborg CI, Wang Z, Imfeld KL, Zaldivar F, Dadufalza V, Buckingham BA. Decreased IL-4 production in new onset type I insulin-dependent diabetes mellitus. J Immunol 1996; 157: 4690-4696